Company
.:[TICKER]
Peak Asset Management is a boutique investment management firm, headquartered in Melbourne, Australia. The company provides private and institutional investors with access to Australia's most attractive corporate opportunities.
170 stories · page 2 of 2
Patents for CelGro® have previously been granted in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand, and the new US divisional patent further protects and strengthens the IP position by providing greater layers of
The East Melbourne location is expected to increase patient access to Emerald Clinics as well as support pivotal registration trials planned for Emyria’s first drug development program, EMD-003.
The grant aims to boost digital health infrastructure in WA and will involve monitoring the vital signs and mental health of at-risk individuals and confirmed COVID-19 individuals.
The Prosthesis list defines the minimum amount of benefit to be paid by private insurers for CelGro®product used in approved dental bone and soft tissue repair procedures.
CelGro represents a breakthrough in soft tissue reconstruction and offers commercial potential in existing addressable markets of bone, tendon, nerve and cartilage, and wider applications in general surgical and soft tissue reconstructive a
The appointment will support Emyria’s multiple mental health focussed initiatives targeting unmet needs in mental health including the initial drug development program - EMD-003 - targeting psychological distress and related problems.
The case study has proven that CelGro®, combined with Ortho-ATI® is effective in returning a patient to normal function and has been published in the International Journal of Case Reports.
It believes the increasing interest and support for high-quality RWE from the FDA, particularly in the field of cannabinoid medicines, bodes well for its strategy to use its proprietary data platform and unique RWE assets to inform and supp
The company grew revenues by 200% from the September 2020 quarter.
The funds will be invested into the Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals, and to advance the development and commercialisation of Ortho-ATI®.
US market clearance provides a pathway for OCC to continue driving the development of CelGro collagen medical device in the key peripheral nerve repair application, and it will pursue negotiations with multi-national dental companies for ma
The company recently received the green light to introduce its CelGro® collagen medical device into the Australian dental bone and tissue regeneration market.
In parallel to the TGA-registration plan, Emyria will also design its EMD-003 registration studies to meet the requirements of other global regulatory bodies.
The drug programs target major unmet medical needs and will pursue formal registration with major regulators bodies, including the Therapeutic Goods Administration (TGA).
The approval positions Orthocell well for US Food and Drug Administration (FDA) approval, targeted for 2021.
The company has successfully completed the Australian TGA Conformity Assessment process around the safety and performance of CelGro® in dental bone and tissue regeneration procedures.
The company is well-placed to achieve milestones related to registering its leading drug development programs, each addressing a major unmet need - EMD-003 focused on mental health and EMD-004 focused on irritable bowel syndrome (IBS).
With its access to data and clinical care arm, the company is in a unique position to generate clinical evidence for the safety and efficacy of its new cannabis product for mental health applications.
Emyria is undertaking this observational study as an important step towards generating evidence of efficacy and safety for routinely prescribed medicinal cannabis for the management of symptoms in patients with irritable bowel syndrome (IBS
The program is designed to support the registration of a specific cannabinoid-based medicine for a specific mental health indication with the TGA's Australian Register of Therapeutic Goods.
The regenerative medicine company is now progressing regulatory applications in Australia and will start a US regulatory study shortly.
It will leverage on Emyria’s experience with unregistered medicines for patients with unmet needs across its national network of clinics – Emerald Clinics
The paper ’Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’ reports positive results from pre-clinical and clinical study results for the CelGro treatment.
The chairman has made several purchases this month totalling 775,000 ordinary shares valued at more than $61,267, bringing the total shares held in direct and indirect interests to almost 49.326 million.
This deal leverages Emyria’s real-world data expertise and national network of clinics – Emerald Clinics - to facilitate patient access.
The funds will be invested into accelerating the commercialisation of Emyria’s data products, technologies and supporting internal data analysis.
The company has partnered with Mt Sinai Hospital’s Precision Recovery team in New York to support ongoing development of Emyria’s Openly clinical service for the remote monitoring of patients and care coordination.
It will provide a new source of data to bolster Emyria’s growing cannabinoid data platform and allow Emyria to leverage Sapphire’s resources and infrastructure in the UK to provide services to UK patients.
The healthcare technology and services company is taking a leadership role in digitally-connected and patient-centric healthcare that also generates high-quality clinical evidence where it matters most, in the real world.
Emyria will provide real-world data that will complement the existing clinical data-pack for Zenivol™ and be used to inform further clinical development and, ultimately, the path to product registration.
The company has partnered with Mt Sinai Hospital’s Precision Recovery team to support ongoing development of Emerald’s Openly clinical service for the remote monitoring of patients and care coordination.
The paper ’Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’ reports positive results from pre-clinical and clinical study results for the CelGro treatment.
The company’s portfolio of regenerative medicine products have shown in clinical studies and real world evidence to return patients to work, activities of daily living and elite sport pain-free.
The Openly technology extends Emerald’s real-world-evidence (RWE) platform and aids Emerald’s clinical team to provide remote health and wellness screening for patients and workforces.
The SAS product use also provides real-world evidence for the safety and efficacy of CelGro®, further validating data collected in clinical trials.
The company’s strategy of generating high-quality clinical evidence on the safety and efficacy of new treatments, including CBD, makes it well-positioned to benefit from the changes announced by the TGA.
The company achieved a record month in July and closed a major data deal in the UK.
The company proposes its name change to Emyria Limited will support its expanded offerings in remote chronic disease management, digital health technology development and COVID health screening
The company proposes that the name change to Emyria Limited will support its expanded offerings in remote chronic disease management, digital health technology development and COVID health screening.
Emerald will leverage its extensive data expertise to monitor the safety, efficacy and pharmacoeconomics of specific medicinal cannabis products.
The healthcare technology and services company joined the global fight against COVID-19 by taking the lead as program manager for the development of a National Clinical Data and Analytical Platform.
The company’s commercialisation strategy for the product will leverage the TGA results for regulatory submission in the US.
The trademark will remain in force for an initial period of 10 years and may be renewed for successive periods of 10 years thereafter.
The study captures patient feedback/outcomes for reduction of pain, functional improvement and overall satisfaction, in patients suffering from chronic tendon injuries
The firm's technology can count people via sensor to maintain capacity restriction and can analyze CCTV footage to monitor social distancing and face mask detection
The companies will begin the trial to assess the effectiveness of Ortho-ATI, a novel cell therapy developed to treat chronic tendon injuries.
The company’s expanded remote monitoring digital health platform, Sentinel Plus, will use Binah.ai technology and could support companies, universities and governments to monitor health of their personnel remotely.
The company’s real-world evidence data platform provide insights into the safe and effective use of medicines, to improve patient care, and to identify novel uses of existing or new therapeutics.
Proactive's mining analyst, Dr Ryan D Long, catches up with the Mike Ralston, the CEO of Blencowe Resources. Blencowe is currently undertaking a 1,800-metre drill programme and is targeting the production of a maiden JORC-compliant mineral
With a leading regenerative medicine portfolio and experienced senior advisory team, Orthocell is well-positioned to drive its products into the US, EU and AU markets.
The therapy features in a chapter of the book which has been downloaded more than 3,000 times.
A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective.
The project has been established by the Digital Health Cooperative Research Centre and is a partnership between NSW Health, Queensland Health, QUT, the University of Sydney and Monash University.
During the quarter, the company continued its clinician advocacy program to expand the network of referring clinicians and product use in centres of excellence.
The company manages an independent clinical service and data platform designed to capture, analyse and provide new insights into these real-world issues and provide valuable anonymous data on a subscription payment, or data acquisition mode
The company believes there is potential to extend its real-world evidence (RWE) platform to support the growing need to monitor COVID-19 patients.
The regenerative medicine company is focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries.
The company believes there is potential to extend its real-world evidence (RWE) platform to support the growing need to monitor COVID-19 patients.
The acquisition of Minera Don Nicolas sets Cerrado on track to become an intermediate gold producer in South America
These results on-top of earlier drilling indicate the potential for a large gold deposit at El Zorro with three holes of a planned 10-hole program completed.
Emerald operates a network of clinics specialised in assessing the safety and efficacy of unregistered medicines including cannabinoid medicines.
The company specialises in the appropriate use of unregistered medicines, including cannabinoid treatments, and the creation of robust and ethically sourced real-world clinical evidence.
The company is drilling at the El Zorro Gold Project to extend the mineralised zone at Coquetas which has previously reported multiple, wide, high-grade gold intersections.
The collagen ropes enhance soft tissue repairs to areas such as anterior cruciate ligaments or ACLs.
Investments and investor services
Despite a sharp price correction in 2018, shrinking supply sources and growing demand for battery chemicals are predicted to sustain cobalt prices into the 2020s.
Investments and investor services
Despite its enormous potential as a new energy mineral, steel remains the primary price driver for vanadium.
Investments and investor services
Price corrections were the norm for base metals in 2018 and ongoing uncertainty around trade has offset price upside from declining supply and stronger demand.
The oil industry faces political and financial uncertainty as global production is curtailed to prop up the volatile price of crude.
The lithium price faces a slow downward trend to 2022 as the market shifts into a supply surplus in 2019.
Investments and investor services
Sustained demand growth and forecast supply cuts have not yet translated into higher copper prices as the Chinese economy slows.
